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Objectives: Omalizumab is a humanised anti-IgE recombinant monoclonal anti-
body approved in Turkey for treatment of chronic idiopathic (or spontaneous) urti-
caria (CIU) in patients resistant to standard treatment. We aimed to assess the 
cost-effectiveness of omalizumab compared with the standard care in the treatment 
of CIU patients in Turkey. MethOds: A Markov model of 10 years horizon was devel-
oped to estimate costs and outcomes associated with omalizumab 300mg/every 4 
weeks and standard of care for 24 weeks (SoC= licensed dose H1 antihistamines) 
using data from two phase III studies (ASTERIA I&II includes patients with CIU 
refractory to licensed dose of H1-antihistamines). The study was undertaken from 
a Turkish health care payer perspective. At the end of this period, omalizumab was 
stopped and background medication continued. Patients who have responded were 
retreated by the same strategy upon relapse (UAS7 ≥ 16 or ≥ 28). We used Urticaria 
Activity Score 7 (UAS7) to measure the outcome of the treatment and we used 
symptom free days (UAS7 ≤ 6) as the outcome measure in this cost effectiveness 
analysis. Resource utilization data were obtained via a Delphi panel. Unit costs 
were taken from the Social Security Institution’s official list. Costs and outcomes 
were evaluated over a lifetime and discounted at 3%. Results were presented as 
incremental cost/symptom free days. Results: The incremental symptom free 
days with omalizumab versus SoC was 27,965 days and the incremental cost was 
1,610,349 Turkish Liras for 100 patients over 10 years. The incremental cost per 
symptom free day was 57.59 Turkish Liras. One-way sensitivity analyses confirmed 
the robustness of the model results. cOnclusiOns: CIU affects the quality of life 
of patients and is associated with direct and indirect costs to payers and society. 
We believe that omalizumab 300mg Q4wks is a cost-effective treatment option for 
patients with refractory CIU in Turkish setting.
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Objectives: To evaluate the efficacy of treatment with ranibizumab in a sample of 
Greek patients with nAMD. MethOds: In this observational, non-interventional, 
retrospective study, 194 cases with nAMD were enrolled from the Ophthalmology 
Department of “Attikon” hospital. Patients treated with ranibizumab for at least one 
year in one eye under routine clinical practice, and had at least one follow-up visit, 
were considered eligible. Patients participating in another study and/or were receiv-
ing pharmaceutical product containing VEGF inhibitors were excluded. Primary end-
points were the mean change in Best Corrected Visual Acuity (BCVA), and in Central 
retinal thickness (CRT), assessed by Optical Coherence Tomography. Results: 
The average BCVA score per eye at baseline was 0.284 in decimal points (Snellen 
equivalent≈ 20/84; ETDRS letters≈ 57.7), which improved at final visit (≈14 months 
after baseline) reaching 0.336 (Snellen equivalent≈ 20/60; ETDRS letters≈ 61.3), i.e. 
6,33% or approximately 3.7 ETDRS letters improvement (p< 0.001, r= 0.317) with 4.9 
ranibizumab injections overall (4.3 injections/year). CRT similarly improved, as it 
decreased by 28.4%, from 290.31 to 207.77 μ m (p< 0.001, r= 0.683). An extra ranibi-
zumab injection per eye per year, increased the odds of an at least 0.1 increase in 
BCVA from baseline to last visit by 20.8% (95%CI 1.068-1.366), and an at least 0.2 
increase by 15.7% (95%CI 1.013-1.322). cOnclusiOns: Ranibizumab provides sig-
nificant benefit in patients with nAMD under routine clinical practice by improving 
BCVA and reducing CRT, benefit which may be more important in a more frequent 
dosing regimen.
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Objectives: Background: The project focused on the preventive use, effectiveness 
and the better knowledge about the potential effects and mechanisms of dress-
ings. Aims: To improve the effectiveness of wound care, to prevent effectively the 
appearance of pressure ulcers during hospitalization. MethOds: During 2 months 
of the project 80 patients of 3 active and 2 chronic care departments were involved, 
treatment of 84 pressure ulcers of 46 patients occurred. After the health check the 
attachment of dressings and the wound management were carried out according 
to the protocols and were documented on special datasheets. Subsequently, the 
checking and processing of questionnaires – continuing the monitoring of patient 
pathways – were done. Results: Pressure ulcers did not develop in case of 79% of 
the patients after prevention, effectiveness of targeted prevention reached 95.5%. 
The incidence of decubitus fell by 1.6-1.7 % in the project (formation rate was 58.8-
90.9 % lower in average). In the background of successful prevention min. 3-day use 
was observed, but even use of 1-1 preventive dressing was effective. The average 
length of wound care was14 days, frequency was 8.2 times/patient. The healed or 
recovering wounds were more frequently treated, but rather for more days, how-
ever, their treatment cost less than the average and those wounds which were not 
healing. cOnclusiOns: Wound care starts with prevention. The quality of wound 
care should not decrease after the patient’s discharge, the home follow-up would 
be essential, nevertheless its “best practices” has not spread widely in Hungary yet. 
In the short term Decubitus Team doctors should be involved in patients’ discharge 
planning, however in the long term creation of a so-called Wound Care Centre could 
offer a sustainable solution. Hereinafter controlled trials of higher number of cases 
could prove the cost-effectiveness of intelligent dressings in wider aspects of the 
health care system.
tobacco tax is important as a source of revenue. The objectives of this research is to 
quantitatively assess about how general public value several aims of tobacco policy 
and the amount of tax revenue and to estimate “ideal” tobacco price where the price 
elasticity of tobacco consumption is given. MethOds: We conducted a web-based 
survey from 9-15, Aug 2012 including a discrete choice experiment (DCE) to elicit 
general public’s preference for targeted smoking rate, tax revenue, tobacco policy for 
the younger generation and the usage of tax. Then, we numerically forecast general 
publics’ support rate of a tobacco policy as a function of tobacco price where price 
elasticity is given. Results: 1,077 completed questionnaires and were eligible for 
analysis. They statistically prefer the tobacco policy which results in lower prevalence 
of smokers, higher tax revenue, targeted for young people and tax revenue is used for 
general purposes. Given the price elasticity of 0.3, 0.4 and 0.5, highest tobacco price, 
which acquire the highest support from general public, was around JPY871 (EUR6.2), 
JPY555 (EUR4.0) and JPY454 (EUR3.2), respectively. cOnclusiOns: The present price 
of cigarette per one pack is around JPY460 (EUR 3.3). When smokers are highly respon-
sive to price elevation and are successfully quit after the elevation, present price of 
cigarette is suitable when we consider public’s preference for tax revenue as well as 
normal policy measures. Rooms for further price elevations depends on the price 
elasticity of cigarette consumption.
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Objectives: To indirectly compare the efficacy of approved treatments for 
macular oedema secondary to branch retinal vein occlusion (BRVO). MethOds: 
Randomized, controlled trials (RCTs) evaluating the efficacy at month 6 (or month 
12) of at least two of ranibizumab 0.5mg pro re nata (after 6 monthly doses), afliber-
cept 2.0mg monthly, dexamethasone implant (retreatment interval ≥ 6 months), 
laser photocoagulation or sham were identified from a published systematic 
review, congress abstracts, clinicaltrials. gov and Novartis data on file. Outcomes of 
interest were the mean change in best-corrected visual acuity (BCVA, measured as 
Early Treatment Diabetic Retinopathy Study letters), and the percentage of patients 
gaining ≥ 15 letters. For two studies, the standard deviation around mean BCVA 
gain was estimated. A Bayesian network meta-analysis with random treatment 
effects was used to compare mean BCVA gains and odds ratios (ORs) for gaining 
≥ 15 letters. Results: The analysis included seven RCTs. Patient-level data for 
three ranibizumab trials were re-analysed to match key inclusion criteria (BCVA 
and duration of disease at baseline) from aflibercept studies. Statistically signifi-
cant (p< 0.05) BCVA letter gains were found for ranibizumab monotherapy (+11.6), 
ranibizumab plus laser combination therapy (+10.1) and aflibercept (+10.1) versus 
laser, and for ranibizumab monotherapy versus dexamethasone (+8.0). ORs versus 
laser for gaining ≥ 15 letters were 3.24 (95% credible interval, 1.03–12.56; p< 0.05) 
and 3.07 (0.63–14.8) for ranibizumab monotherapy and aflibercept, respectively. 
Mean BCVA letter gains were numerically higher with ranibizumab monotherapy 
compared with aflibercept (+1.5 letters [-5.3–8.8]; OR for gaining ≥ 15 letters, 1.06 
[0.16–8.94]). The probability of being the most efficacious treatment based on let-
ters gained was 57% for ranibizumab, 15% for ranibizumab plus laser and 28% for 
aflibercept. cOnclusiOns: The analysis confirms the superiority of ranibizumab 
over dexamethasone implant and laser therapy, and shows that ranibizumab has 
the highest likelihood of being the most efficacious treatment for BRVO.
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Objectives: Recently, advanced treatments such as topical growth factors, bio-
logical dressings, and tissue engineered products have been developed in order 
to promote healing as well as decrease the time to healing of chronic leg ulcers. 
Nevertheless, if standard care fails, there is no widely accepted, easy to use second-
line treatment primarily because most of these advanced treatments are expensive 
and need further evidence of effectiveness in everyday clinical practice. The purpose 
of our study was to assess the effectiveness of a new acellular synthetic matrix 
(ASM) as an adjunct to standard care, using healing time as endpoint, in venous and 
mixed leg ulcers in German everyday clinical practice. MethOds: Prospective data 
on venous and mixed leg ulcers from a safety and effectiveness study on an acellular 
synthetic matrix was compared retrospectively to matched data from a German 
Registry of Chronic Wounds (DRCW) database containing German patients with 
equivalent leg ulcer disease, patient age and gender, baseline wound area, wound 
duration, same outcome measures, and comparable follow-up periods. The outcome 
of interest was healing time over 12-weeks of treatment. Results: Analysis using 
Kaplan Meier survival curves showed a mean of 73.1 days (95% CI: 66.4 - 79.9 days) 
to healing for acellular synthetic matrix treated ulcers, in comparison to 92.2 days 
(95% CI: 87.1 – 97.2 days) for equivalent ulcers treated in everyday clinical practice 
in Germany (Log rank test χ 2 11.46, p= 0.001). cOnclusiOns: Results from this 
study predict a highly significant effect of a new acellular synthetic matrix as an 
adjunct to standard care in the repair of venous and mixed leg ulcers. The predic-
tive model may be useful in determining expected effectiveness of the acellular 
synthetic matrix in the treatment of venous and mixed leg ulcer patients treated 
in everyday clinical practice in Germany.
